My main take away points from this Ann is that.
RAC has been working with Zantrene long enough to understand that if they want to get full potential of FTO inhibitor NOT just for Oncology but beyond (many more diseases), by having this program (relatively cheap) Zantrene could potentially be modified to become a Full Drug = Full potential and A New Zantrene would continue to be a leading Clinical Drug in this Hot m6A RNA.
A great beginning journey of Beyond Zantrene.
AIMO
My main take away points from this Ann is that.RAC has been...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |